Approximately 99% of patients with polycythemia vera (PV) harbor the JAK2V617F mutation; however, no targeted therapies for the treatment of PV currently exist. Wernig et al. studied the efficacy of ...
Investigator & Co-Director of the Neurotherapeutics IWI, Lundquist Institute (Formerly "LA BioMed"); Assistant Professor, David Geffen School of Medicine at UCLA Department of Neurology Ataxia ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果